Smith Caitlin H, Stewart Holly L, Stefanovski Darko, Levine David G
Department of Clinical Studies, New Bolton Center, University of Pennsylvania, Philadelphia, PA, United States.
Front Vet Sci. 2025 May 9;12:1559519. doi: 10.3389/fvets.2025.1559519. eCollection 2025.
This study aimed to describe the effect of single implantation of autologous tumor tissue at inducing clinical regression of equine sarcoids. Special emphasis was placed on the influence of concurrent and subsequent therapies, time- independent outcomes, and associated complications. A retrospective review was conducted using medical records from the University of Pennsylvania's New Bolton Center between May 2014 and January 2022. Follow-up data were collected through phone and email surveys. Descriptive statistics were generated, and outcomes were analyzed using univariate and multivariate logistic regression models. Fifty equids that underwent elective autologous tumor tissue implantation were included in the study. Complete resolution without recurrence was observed in 50% of cases. There was no significant difference in outcome between animals treated with autoimplantation alone and those receiving concurrent antineoplastic therapies. Equids with a history of treatment failure were 77% less likely to show improvement. After adjusting for other factors, sarcoids located on the body had 48% lower odds of clinical improvement, and each additional tumor decreased the odds of improvement by 11%. When tumor numbers decreased following initial implantation, the odds of recurrence were reduced by 71%. Two cases (4%) developed tumors at the implantation site. Autologous tumor implantation was most effective in animals with a lower tumor burden and was relatively less successful in cases involving body-localized sarcoids or tumors refractory to previous treatments. Severe complications were uncommon, and client satisfaction trended with incidence of recurrence. The technique is technically simple and may be beneficial in selected cases of equine sarcoids. Further research into the mechanisms may inform the development of future therapies, including potential commercial vaccines.
本研究旨在描述单次植入自体肿瘤组织对诱导马肉瘤临床消退的效果。特别强调了同期及后续治疗的影响、与时间无关的结果以及相关并发症。使用宾夕法尼亚大学新博尔顿中心2014年5月至2022年1月的病历进行回顾性研究。通过电话和电子邮件调查收集随访数据。生成描述性统计数据，并使用单变量和多变量逻辑回归模型分析结果。本研究纳入了50匹接受选择性自体肿瘤组织植入的马属动物。50%的病例观察到完全消退且无复发。单独接受自体植入治疗的动物与接受同期抗肿瘤治疗的动物在结局上无显著差异。有治疗失败史的马属动物病情改善的可能性降低77%。在对其他因素进行调整后，位于身体上的肉瘤临床改善的几率降低48%，每增加一个肿瘤，改善几率降低11%。初次植入后肿瘤数量减少时，复发几率降低71%。有2例（4%）在植入部位出现肿瘤。自体肿瘤植入对肿瘤负荷较低的动物最有效，而在涉及身体局部肉瘤或对先前治疗难治的肿瘤病例中相对不太成功。严重并发症不常见，客户满意度与复发率相关。该技术在技术上简单，可能对部分马肉瘤病例有益。对其机制的进一步研究可能为未来治疗方法的开发提供信息，包括潜在的商业疫苗。
